Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exubera’s change in control

Executive Summary

Pfizer and Sanofi-Aventis are in discussions concerning their partnership for Exubera following a judge's ruling that a "change of control" has occurred in the companies' agreement, Pfizer said during its quarterly earnings call July 20. Pfizer said it now has rights to Exubera under the court's ruling and pursuant to a 1998 agreement between Pfizer and Aventis governing co-marketing of the inhaled insulin. Following Sanofi's acquisition of Aventis in August 2004, Pfizer sued the company in the U.S. and Germany seeking to enforce change of control provisions for Exubera (1"The Pink Sheet" Oct. 25, 2004, p. 17). The Exubera NDA will be reviewed by FDA's Endocrinologic & Metabolic Drugs Advisory Committee on Sept. 8...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS046142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel